Clonal hematopoiesis of indeterminate potential (CHIP) arises from somatic mutations in hematopoietic stem cells (HSCs) that confer a fitness advantage and is associated with increased risks of myeloid neoplasia, cardiovascular disease, and mortality. 1 – 5 Although aging is a major determinant of CHIP, the contributio...
Olisaemeka D. Ogbue, Tariq Kewan, Serhan Unlu et al.· HemaSphere· 0 citations
Germline GATA2 deficiency is a hereditary disorder characterized by immunodeficiency, bone marrow failure, and a high risk of myelodysplastic neoplasms and acute myeloid leukemia (AML). Although abnormalities of innate immunity are well recognized, the phenotype and functional state of CD8
+
T cells remain inco...
Marta Penco, M. Capelletti, Lorenzo Manfreda et al.· Frontiers in Immunology· 0 citations
Most acquired idiopathic bone marrow failure syndromes (BMFS) are thought to be cytotoxic T cell-mediated and are responsive to immunosuppressive therapies (IST) targeting T cells. However, in addition to frequent relapses, a proportion of cases remain refractory to first- and second-line agents due to a lack of clinic...
Serhan Unlu, Aashray Mandala, M. Orland et al.· Leukemia· 0 citations
Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18-40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); sec...
A. J. Jimenez Jimenez, D. Eikema, L. Koster et al.· Bone Marrow Transplantation· 1 citation
Despite treatment advances, relapsed/refractory
FLT3
-ITD-mutated acute myeloid leukemia (
FLT3
-ITD
mut
AML) remains an unmet medical need. We previously identified a CD34/CD123/CD25/CD99+ leukemic progenitor cell (LPC) population that persists after induction treatment and drives disease recurrence in
FLT3...
S. Travaglini, T. Ottone, S. Antonelli et al.· Cell Death Discovery· 0 citations
Introduction
Myelofibrosis (MF) is a BRC::ABL1-negative myeloproliferative neoplasm characterised by a heterogeneous clinical phenotype encompassing abnormalities in blood counts, bone marrow fibrosis, splenomegaly, constitutional symptoms and vascular complications. MF may progress to accelerated phase (AP) and blast...
Barbara Mora, M. Franchi, L. Margotto et al.· Epidemiology Biostatistics a...· 0 citations
Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.
N. Gagelmann, R. Salit, T. Schroeder et al.· Transplantation and Cellular...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.